MENU Quick Go

  • HOME
  • News
  • PharmAbcine Notice
PharmAbcine Notice
Total 201 search
No. Subject Date Count
201 제3자 배정 신주 발행 건 공지 2018-04-16 117
200 제3자 배정 신주 발행 공지 2018-04-12 322
199 파멥신 교모세포종 치료제 ‘TTAC-0001’, FDA 희귀의약품 지정 2018-04-01 311
198 PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme. 2018-04-01 334
197 ``코스닥 재도전하는 파멥신, 반전드라마 주인공될까`` - 바이오스펙테이터 2018-03-28 260
196 `` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model`` is now indexed on PubMed. 2018-03-25 173
195 ``Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2`` is now indexed on PubMed. 2018-03-25 151
194 Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at 9TH CLINICAL TRIALS INNOVATION PROGRAMME on April 26-27, 2018. 2018-03-25 131
193 Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at Asia Pharma R&D Leaders Summit 2018 on April 17-18, 2018. 2018-03-25 139
192 Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at BOSTON CEO on May 10th, 2018. 2018-03-23 177
1 2 3 4 5 6 7 8 9 10